论文部分内容阅读
目的探讨瑞舒伐他汀抗动脉粥样硬化的临床价值和药理作用。方法 60例动脉粥样硬化患者,数字抽取分为研究组与对照组,每组30例。对照组予以阿司匹林治疗,研究组则予以瑞舒伐他汀进行治疗,分析对比两组患者临床治疗效果。结果两组患者经治疗颈动脉内膜中层厚度(IMT)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)指标均得到明显改善,研究组治疗效果优于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀可以明显改善抗动脉粥样硬化症状,具有良好治疗效果,值得临床应用推广。
Objective To investigate the clinical value and pharmacological effects of rosuvastatin on atherosclerosis. Methods Sixty patients with atherosclerosis were randomly divided into study group and control group with 30 cases in each group. The control group was treated with aspirin, while the study group was given rosuvastatin for treatment. The clinical effects of the two groups were compared and analyzed. Results The IMT, TC, TG and LDL-C of the two groups were significantly improved after treatment. The treatment effect of the study group was excellent In the control group, the difference was statistically significant (P <0.05). Conclusion Rosuvastatin can significantly improve anti-atherosclerotic symptoms, with good therapeutic effect, it is worth promoting the clinical application.